Bayer has initiated a Phase I clinical trial of 225Ac-GPC3 (BAY 3547926), a targeted alpha radiopharmaceutical designed to treat advanced hepatocellular carcinoma by delivering potent radiation directly to cancer cells.
The American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago will focus on "Unifying Cancer Science and Medicine" with presentations spanning from basic research to practice-changing clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.